Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab
- PMID: 15466107
- DOI: 10.1542/peds.2004-1300
Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab
Comment on
-
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.Pediatrics. 1998 Sep;102(3 Pt 1):531-7. Pediatrics. 1998. PMID: 9738173 Clinical Trial.
-
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.J Pediatr. 2003 Oct;143(4):532-40. doi: 10.1067/s0022-3476(03)00454-2. J Pediatr. 2003. PMID: 14571236 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical